

Table I. Baseline characteristics of the patients with hepatocellular carcinoma enrolled in this study.

Characteristic	All patients (n=23)	Patients with lenvatinib failure (n=16)
Treatment line, n (%)		
1	7 (30.4)	0
2	15 (65.2)	15 (93.8)
3	1 (4.3)	1 (6.3)
Age, years		
Median (range)	74 (38-85)	74 (38-85)
Gender, n (%)		
Male	18 (78.3)	12 (75.0)
Female	5 (21.7)	4 (25.0)
Etiology, n (%)		
HBV	4 (17.4)	3 (18.8)
HCV	5 (21.7)	4 (25.0)
NBN	14 (60.9)	9 (56.3)
ECOG-PS, n (%)		
0	21 (91.3)	14 (87.5)
1	2 (8.7)	2 (12.5)
Child-Pugh score, n (%)		
5	15 (65.2)	11 (68.8)
6	8 (34.8)	5 (31.3)
mALBI grade, n (%)		
1	5 (21.7)	3 (18.8)
2a	10 (43.5)	8 (50.0)
2b	8 (34.8)	5 (31.3)
BCLC stage, n (%)		
B	8 (34.8)	6 (37.5)
C	15 (65.2)	10 (62.5)
Tumor size, n (%)		
<50 mm	14 (60.9)	11 (68.8)
≥50 mm	9 (39.1)	5 (31.3)
Number of tumors, n (%)		
<4	6 (26.1)	2 (12.5)
≥4	17 (73.9)	14 (87.5)
Portal vein invasion, n (%)		
No	20 (87.0)	14 (87.5)
Yes	3 (13.0)	2 (12.5)
Hepatic vein invasion, n (%)		
No	20 (87.0)	14 (87.5)
Yes	3 (13.0)	2 (12.5)
Bile duct invasion, n (%)		
No	21 (91.3)	15 (93.8)
Yes	2 (8.7)	1 (6.3)
Extrahepatic spread, n (%)		
No	21 (91.3)	15 (93.8)
Yes	2 (8.7)	1 (6.3)
AFP level, ng/ml		
Median (range)	173.6 (2.6-231,724)	152.7 (2.6-231,724)
AFP level, n (%)		
<400 ng/ml	17 (73.9)	12 (75.0)
≥400 ng/ml	6 (26.1)	4 (25.0)
Observation period, days		
Median (range)	95 (53-123)	95 (53-123)

HBV: Hepatitis B virus; HCV: hepatitis C virus; NBNC: non-HBV and non-HCV; ECOG-PS: Eastern Cooperative Oncology Group performance status; mALBI: modified albumin–bilirubin; BCLC: Barcelona Cancer Liver Clinic; AFP: alpha fetoprotein.